ANALYSIS: With an Obermatt 360° View of 75 (better than 75% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock WuXi Biologics (Cayman) are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for WuXi Biologics (Cayman). The consolidated Growth Rank has a good rank of 94, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 94% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 92 which means that the company has a financing structure that is safer than 92% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 28 which means that the share price of WuXi Biologics (Cayman) is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 72% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 22, which means that professional investors are more pessimistic about the stock than for 78% of alternative investment opportunities. ...read more